Author

G. Morton

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Approach:comparative / phylogenetic analysis· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:protein sequence· 1

Frequent Co-Authors

W. Childers· 2 shared A. Cara· 1 shared A. Ciarla· 1 shared A. M. Moody· 1 shared B. Balakumaran· 1 shared B. F. Haynes· 1 shared B. Mildenberg· 1 shared C. LaBranche· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

W. Childers

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination

H. Li, S. Chatla, X. Liu, Z. Tian, U. Vekariya, P. Wang, D. Kim, S. Octaviani, Z. Lian, G. Morton, Z. Feng, D. Yang, K. Sullivan-Reed, W. Childers, X. Yu, , J. Huang

This study identifies ZNF251 haploinsufficiency as a mechanism conferring PARP inhibitor resistance in BRCA1-mutated cancer cells through RAD51-mediated homologous recombination.

bioRxiv · Sep 29, 2022 · PreprintCancer Biology

Comparative Modeling of CDK9 Inhibitors to Explore Selectivity and Structure-Activity Relationships

P. Kirubakaran, G. Morton, P. Zhang, H. Zhang, J. Gordon, M. Abou-Gharbia, J.-P. J. Issa, J. Wu, W. Childers, J. Karanicolas

The paper develops a comparative modeling approach to study CDK9 inhibitor selectivity and structure-activity relationships, using existing PDB data and validating with a crystal structure.

bioRxiv · Jun 8, 2020 · PreprintCancer Biology

Immunogenicity, safety and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs

M. Blasi, D. Negri, K. O. Saunders, E. J. Baker, H. Stadtler, C. LaBranche, B. Mildenberg, G. Morton, A. Ciarla, X. Shen, Y. Wang, W. Rountree, B. Balakumaran, S. Santra, B. F. Haynes, , M. E. Klotman

This study evaluates an SIV-based IDLV vaccine expressing sequential CH505 Envs in rhesus macaques, showing improved antibody responses and virus control but no broadly neutralizing antibodies.

bioRxiv · Mar 6, 2020Immunology